Parkinsonism and DOPA.
D006916:5-Hydroxytryptophan / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use*; D004298:Dopamine / Q000652:urine; D006801:Humans; D008297:Male; D020149:Manganese Poisoning; D008906:Mining; D009784:Occupational Diseases / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy*; D010648:Phenylacetates / Q000652:urine; D010649:Phenylalanine / Q000627:therapeutic use; D010919:Placebos
D010648:Phenylacetates; D010919:Placebos; D010649:Phenylalanine; D004295:Dihydroxyphenylalanine; D006916:5-Hydroxytryptophan; D004298:Dopamine